Carla Grandori, CEO and Founder of SEngine
0:00 Beyond FoundationOne: Screening patient tumor cells against 100’s of drugs
9:28 Why didn’t we do this before?
11:53 The Cancer Biogram
14:00 PARIS test currently being sold to oncologists
20:44 A personal mission: “I think we can help now.”
Carla Grandori was for thirty years a cancer researcher most recently at the Fred Hutch in Seattle. She had her personal reasons for working on cancer, she tells us in today’s show. Now, she’s the CEO and founder of SEngine, a startup offering something completely new for oncologists around the country.
Carla says she was motivated to step out of the research lab when two patients came to her personally and asked her, “can you study my cancer?”
“When I heard that second request, a light went off. I had thought maybe in 10 years the research would be useful. But then this patient made me think, ‘no, I think we can help now.' When I realized the potential of our technology to help patients immediately, I saw no more boundaries. I said, 'we have to get there.’"
What is this technology? And if it’s so powerful, why hasn’t it been offered before?
SEngine's (think Search Engine) new test, called PARIS, screens individual patient tumor cells onsite against a complete library of over a hundred and fifty cancer drugs. Before now with say, Foundation Medicine, there has been much progress in sequencing tumors and offering lots of omics data virtually. But the PARIS test goes a step further, screening a patient’s actual cells in real time while also combing through accompanying omics data. Until now we didn’t have the technology to deal with the samples with enough precision and in small enough quantities, nor the necessary robotics and software.
The company received CLIA certification back in June and the test is for sale to oncologists now. The next step for SEngine is to build up a major clinical utility validation.